Current treatment options for waldenström macroglobulinemia

Arun Vijay, Morie A. Gertz

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Waldenström macroglobulinemia (WM) is a lymphoma characterized by lymphoplasmacytic bone marrow infiltration and elevated immunoglobulin M levels. Effective treatment modalities exist for this disease but no cure. We review available treatment modalities, the findings of relevant and comparative recent clinical trials, and the latest therapeutic advances in the management of patients with WM. Alkylating agents, nucleoside analogues, monoclonal antibodies, and proteasome inhibitors have been studied as single therapeutic agents and as combination therapies. The encouraging results of combination regimens have resulted in their use as first-line and salvage treatments. Further clinical trials are required before a specific regimen can be recommended.

Original languageEnglish (US)
Pages (from-to)219-229
Number of pages11
JournalClinical Lymphoma and Myeloma
Issue number4
StatePublished - Aug 1 2008


  • Alkylating agents
  • Lymphoplasmacytic lymphoma
  • Marrow transplantation
  • Monoclonal antibodies
  • Purine nucleoside analogues

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Current treatment options for waldenström macroglobulinemia'. Together they form a unique fingerprint.

Cite this